标签归档：btk

多肽定制BTK derived peptide 编码

发表于由
回复

上海金畔生物科技有限公司可以定制不同序列多肽，可以访问官网了解更多产品信息。

名称 BTK derived peptide
编码
别名 BTK derived peptide
纯度 80%，90%，95%，98%，99%
重量 1mg,5mg,10mg,50mg,100mg,1g
序列（单字母缩写） KKVVALYDYMPMN-NH2
序列（三字母缩写） Lys-Lys-Val-Val-Ala-Leu-Tyr-Asp-Tyr-Met-Pro-Met-Asn-NH2
基本描述
溶解度
分子量 1570.95
化学式 C72H115N17O18S2
存储条件 Store at -20°C. Keep tightly closed. Store in a cool dry place.
注释
Documents BTK derived peptide 编码
Figures BTK derived peptide 编码
Reference
C端
N端
化学桥

CNX-500

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

CNX-500  纯度: 98.49%

CNX-500 是一种由与生物素化学连接的共价 Btk 抑制剂 (CC-292) 组成的探针。CNX-500 保留了对 Btk 的抑制活性 (IC50 为 0.5 nM) 以及与 Btk 形成共价键的能力。CNX-500 对激酶表皮生长因子受体和上游 Src 家族激酶 (包括 Syk 和 Lyn) 的抑制作用较低。

CNX-500

CNX-500 Chemical Structure

CAS No. : 1202758-21-1

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥58150 In-stock
5 mg ￥35000 In-stock
10 mg ￥55000 In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

CNX-500 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus

生物活性

CNX-500 is a probe consisting of a covalent Btk inhibitor (CC-292) chemically linked to biotin. CNX-500 retains inhibitory activity against Btk (IC50 of 0.5 nM) and the ability to form a covalent bond with Btk. CNX-500 has low inhibitory effects on kinase epidermal growth factor receptor, and upstream Src-family kinases including Syk and Lyn[1].

体外研究
(In Vitro)

Used in a competition assay, CNX-500 detects free, uninhibited Btk and is excluded from interaction with Btk previously bonded by CC-292. In Ramos cells exposed to a range of CC-292 concentrations, the amount of Btk captured by the probe is compared with untreated samples and the extent of Btk bonded is demonstrated to be proportional to CC-292 drug concentration[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

961.18

Formula

C48H68N10O9S
CAS 号

1202758-21-1
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 50 mg/mL (52.02 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.0404 mL 5.2019 mL 10.4039 mL
5 mM 0.2081 mL 1.0404 mL 2.0808 mL
10 mM 0.1040 mL 0.5202 mL 1.0404 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 1.25 mg/mL (1.30 mM); Clear solution

    此方案可获得 ≥ 1.25 mg/mL (1.30 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 1.25 mg/mL (1.30 mM); Clear solution

    此方案可获得 ≥ 1.25 mg/mL (1.30 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
  • 3.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 1.25 mg/mL (1.30 mM); Clear solution

    此方案可获得 ≥ 1.25 mg/mL (1.30 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Evans EK, et al. Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans. J Pharmacol Exp Ther. 2013 Aug;346(2):219-28.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

BTK IN-1(Synonyms: SNS062 analog)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

BTK IN-1 (Synonyms: SNS062 analog) 纯度: 98.91%

BTK IN-1 (SNS062 analog) 是一种有效的 BTK 抑制剂，IC50 值 <100 nM。

BTK IN-1(Synonyms: SNS062 analog)

BTK IN-1 Chemical Structure

CAS No. : 1270014-40-8

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥1210 In-stock
5 mg ￥1100 In-stock
10 mg ￥1600 In-stock
50 mg ￥4800 In-stock
100 mg ￥7800 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

BTK IN-1 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Immunology/Inflammation Compound Library
  • Kinase Inhibitor Library
  • Protein Tyrosine Kinase Compound Library
  • Anti-Cancer Compound Library
  • Anti-Blood Cancer Compound Library

生物活性

BTK IN-1 (SNS062 analog) is a potent BTK inhibitor, with an IC50 of <100 nM.

IC50 & Target

BTK[1]
体外研究
(In Vitro)

BTK IN-1 (Compound 21) is a potent BTK inhibitor, with an IC50 of <100 nM.

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

384.86

Formula

C19H21ClN6O
CAS 号

1270014-40-8
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : ≥ 100 mg/mL (259.83 mM)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.5983 mL 12.9917 mL 25.9835 mL
5 mM 0.5197 mL 2.5983 mL 5.1967 mL
10 mM 0.2598 mL 1.2992 mL 2.5983 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 3 mg/mL (7.80 mM); Clear solution

    此方案可获得 ≥ 3 mg/mL (7.80 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 30.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 3 mg/mL (7.80 mM); Clear solution

    此方案可获得 ≥ 3 mg/mL (7.80 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 30.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Minna Bui, et al. Heteroaryl btk inhibitors. WO2011029043A1

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

QL-X-138

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

QL-X-138 

QL-X-138 是一种有效和选择性的 BTK/MNK 双激酶抑制剂，表现出与 BTK 的共价结合和与 MNK 的非共价结合。QL-X-138 对 BTK、MNK1 和 MNK2 激酶的 IC50 值分别为 9.4 nM、107.4 nM 和 26 nM。QL-X-138 还显示出抗登革热病毒 2 活性，IC50 值为 3.5 μM。QL-X-138 可用于 B 细胞恶性肿瘤的研究。

QL-X-138

QL-X-138 Chemical Structure

CAS No. : 1469988-63-3

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

QL-X-138 is a potent and selective BTK/MNK dual kinase inhibitor, exhibits covalent binding to BTK and non-covalent binding to MNK. QL-X-138 shows IC50s of 9.4 nM, 107.4 nM and 26 nM for BTK, MNK1 and MNK2 kinases respectively. QL-X-138 also shows anti-dengue virus 2 activity, with an IC50 of 3.5 μM. QL-X-138 can be used for the research of B-cell malignancies[1][2].

体外研究
(In Vitro)

QL-X-138 (72 h) exhibits anti-proliferation activity against lymphoma and leukemia cell lines, with an GI50s of 0.31, 1.2, 0.49,1.4, 0.4, 0.23, 0.95, 1.2, 1.4, 0.23, 1.3, 0.93, 1, and 2.4 μM for TMD8, U2932, Ramos, OCI-AML3, SKM-1, NOMO-1, NB4, HEL, U937, NALM6, MEC-1, MEC-2, Hs 505.T and REC-1 cells, respectively[1].
QL-X-138 (0.5-5 μM; 24-72 h) arrests the progression of Ramos, OCI-AML-3, U937 and U2932 cells cycle in a dose dependent manner[1].
QL-X-138 (0.5-5 μM; 8-72 h) induces apoptosis of Ramos, OCI-AML-3, U937 and U2932 cells in a time- and dose-dependent manner[1].
QL-X-138 (3-10000 nM; 4 h) blocks BTK- and MNK-mediated signaling in lymphoma and leukemia cell[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line: Ramos, OCI-AML3, U2932, TMD8 and U937 cells
Concentration: 3, 10, 30, 100, 300, 1000, 3000, 10000 nM
Incubation Time: 4 hours
Result: Significantly suppressed BTK auto-phosphorylation of Y223 (EC50=11 nM).
Strongly blocked phosphorylation of the BTK downstream target PLCγ2 Y1217 (EC50=57 nM).
Suppressed the phosphorylation of the MNK downstream target eIF4E S209 at a concentration of 1 μM.

分子量

421.45

Formula

C25H19N5O2
CAS 号

1469988-63-3
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Wu H, et, al. Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia. Leukemia. 2016 Jan;30(1):173-81.

    [2]. Wispelaere M, et, al. Discovery of host-targeted covalent inhibitors of dengue virus. Antiviral Res. 2017 Mar;139:171-179.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

QL-X-138

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

QL-X-138 

QL-X-138 是一种有效和选择性的 BTK/MNK 双激酶抑制剂，表现出与 BTK 的共价结合和与 MNK 的非共价结合。QL-X-138 对 BTK、MNK1 和 MNK2 激酶的 IC50 值分别为 9.4 nM、107.4 nM 和 26 nM。QL-X-138 还显示出抗登革热病毒 2 活性，IC50 值为 3.5 μM。QL-X-138 可用于 B 细胞恶性肿瘤的研究。

QL-X-138

QL-X-138 Chemical Structure

CAS No. : 1469988-63-3

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

QL-X-138 is a potent and selective BTK/MNK dual kinase inhibitor, exhibits covalent binding to BTK and non-covalent binding to MNK. QL-X-138 shows IC50s of 9.4 nM, 107.4 nM and 26 nM for BTK, MNK1 and MNK2 kinases respectively. QL-X-138 also shows anti-dengue virus 2 activity, with an IC50 of 3.5 μM. QL-X-138 can be used for the research of B-cell malignancies[1][2].

体外研究
(In Vitro)

QL-X-138 (72 h) exhibits anti-proliferation activity against lymphoma and leukemia cell lines, with an GI50s of 0.31, 1.2, 0.49,1.4, 0.4, 0.23, 0.95, 1.2, 1.4, 0.23, 1.3, 0.93, 1, and 2.4 μM for TMD8, U2932, Ramos, OCI-AML3, SKM-1, NOMO-1, NB4, HEL, U937, NALM6, MEC-1, MEC-2, Hs 505.T and REC-1 cells, respectively[1].
QL-X-138 (0.5-5 μM; 24-72 h) arrests the progression of Ramos, OCI-AML-3, U937 and U2932 cells cycle in a dose dependent manner[1].
QL-X-138 (0.5-5 μM; 8-72 h) induces apoptosis of Ramos, OCI-AML-3, U937 and U2932 cells in a time- and dose-dependent manner[1].
QL-X-138 (3-10000 nM; 4 h) blocks BTK- and MNK-mediated signaling in lymphoma and leukemia cell[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line: Ramos, OCI-AML3, U2932, TMD8 and U937 cells
Concentration: 3, 10, 30, 100, 300, 1000, 3000, 10000 nM
Incubation Time: 4 hours
Result: Significantly suppressed BTK auto-phosphorylation of Y223 (EC50=11 nM).
Strongly blocked phosphorylation of the BTK downstream target PLCγ2 Y1217 (EC50=57 nM).
Suppressed the phosphorylation of the MNK downstream target eIF4E S209 at a concentration of 1 μM.

分子量

421.45

Formula

C25H19N5O2
CAS 号

1469988-63-3
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Wu H, et, al. Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia. Leukemia. 2016 Jan;30(1):173-81.

    [2]. Wispelaere M, et, al. Discovery of host-targeted covalent inhibitors of dengue virus. Antiviral Res. 2017 Mar;139:171-179.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

QL-X-138

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

QL-X-138 

QL-X-138 是一种有效和选择性的 BTK/MNK 双激酶抑制剂，表现出与 BTK 的共价结合和与 MNK 的非共价结合。QL-X-138 对 BTK、MNK1 和 MNK2 激酶的 IC50 值分别为 9.4 nM、107.4 nM 和 26 nM。QL-X-138 还显示出抗登革热病毒 2 活性，IC50 值为 3.5 μM。QL-X-138 可用于 B 细胞恶性肿瘤的研究。

QL-X-138

QL-X-138 Chemical Structure

CAS No. : 1469988-63-3

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

QL-X-138 is a potent and selective BTK/MNK dual kinase inhibitor, exhibits covalent binding to BTK and non-covalent binding to MNK. QL-X-138 shows IC50s of 9.4 nM, 107.4 nM and 26 nM for BTK, MNK1 and MNK2 kinases respectively. QL-X-138 also shows anti-dengue virus 2 activity, with an IC50 of 3.5 μM. QL-X-138 can be used for the research of B-cell malignancies[1][2].

体外研究
(In Vitro)

QL-X-138 (72 h) exhibits anti-proliferation activity against lymphoma and leukemia cell lines, with an GI50s of 0.31, 1.2, 0.49,1.4, 0.4, 0.23, 0.95, 1.2, 1.4, 0.23, 1.3, 0.93, 1, and 2.4 μM for TMD8, U2932, Ramos, OCI-AML3, SKM-1, NOMO-1, NB4, HEL, U937, NALM6, MEC-1, MEC-2, Hs 505.T and REC-1 cells, respectively[1].
QL-X-138 (0.5-5 μM; 24-72 h) arrests the progression of Ramos, OCI-AML-3, U937 and U2932 cells cycle in a dose dependent manner[1].
QL-X-138 (0.5-5 μM; 8-72 h) induces apoptosis of Ramos, OCI-AML-3, U937 and U2932 cells in a time- and dose-dependent manner[1].
QL-X-138 (3-10000 nM; 4 h) blocks BTK- and MNK-mediated signaling in lymphoma and leukemia cell[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line: Ramos, OCI-AML3, U2932, TMD8 and U937 cells
Concentration: 3, 10, 30, 100, 300, 1000, 3000, 10000 nM
Incubation Time: 4 hours
Result: Significantly suppressed BTK auto-phosphorylation of Y223 (EC50=11 nM).
Strongly blocked phosphorylation of the BTK downstream target PLCγ2 Y1217 (EC50=57 nM).
Suppressed the phosphorylation of the MNK downstream target eIF4E S209 at a concentration of 1 μM.

分子量

421.45

Formula

C25H19N5O2
CAS 号

1469988-63-3
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Wu H, et, al. Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia. Leukemia. 2016 Jan;30(1):173-81.

    [2]. Wispelaere M, et, al. Discovery of host-targeted covalent inhibitors of dengue virus. Antiviral Res. 2017 Mar;139:171-179.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

BTK inhibitor 19

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

BTK inhibitor 19 

BTK inhibitor 19 是一种高选择性 BTK 共价抑制剂（IC50 = 2.7 nM）。

BTK inhibitor 19

BTK inhibitor 19 Chemical Structure

CAS No. : 2557174-19-1

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

BTK inhibitor 19 is a highly selective, covalent BTK inhibitor (IC50 = 2.7 nM).

分子量

527.50

Formula

C25H24F3N7O3
CAS 号

2557174-19-1
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Ma C, et al. Discovery of 1-Amino-1H-imidazole-5-carboxamide Derivatives as Highly Selective, Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitors. J Med Chem. 2021 Nov 11;64(21):16242-16270.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

BTK inhibitor 19

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

BTK inhibitor 19 

BTK inhibitor 19 是一种高选择性 BTK 共价抑制剂（IC50 = 2.7 nM）。

BTK inhibitor 19

BTK inhibitor 19 Chemical Structure

CAS No. : 2557174-19-1

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

BTK inhibitor 19 is a highly selective, covalent BTK inhibitor (IC50 = 2.7 nM).

分子量

527.50

Formula

C25H24F3N7O3
CAS 号

2557174-19-1
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Ma C, et al. Discovery of 1-Amino-1H-imidazole-5-carboxamide Derivatives as Highly Selective, Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitors. J Med Chem. 2021 Nov 11;64(21):16242-16270.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

BTK inhibitor 19

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

BTK inhibitor 19 

BTK inhibitor 19 是一种高选择性 BTK 共价抑制剂（IC50 = 2.7 nM）。

BTK inhibitor 19

BTK inhibitor 19 Chemical Structure

CAS No. : 2557174-19-1

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

BTK inhibitor 19 is a highly selective, covalent BTK inhibitor (IC50 = 2.7 nM).

分子量

527.50

Formula

C25H24F3N7O3
CAS 号

2557174-19-1
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Ma C, et al. Discovery of 1-Amino-1H-imidazole-5-carboxamide Derivatives as Highly Selective, Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitors. J Med Chem. 2021 Nov 11;64(21):16242-16270.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

BTK-IN-11

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

BTK-IN-11 

BTK-IN-11 是一种有效的 BTK 抑制剂。BTK在分别由B细胞和骨髓细胞中的 B 细胞抗原受体 (BCR) 和 Fcγ 受体 (FcγR) 介导的信号传导中起重要作用。BTK-IN-11 具有研究相关疾病的潜力，尤其是自身免疫性疾病、炎症性疾病或癌症 (摘自专利 WO2022063101A1，化合物 Z2)。

BTK-IN-11

BTK-IN-11 Chemical Structure

CAS No. : 2765852-46-6

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

BTK-IN-11 is a potent inhibitor of BTK. BTK plays an important role in signaling mediated by B cell antigen receptor (BCR) and Fcγreceptor (FcγR) in B cells and myeloid cells, respectively. BTK-IN-11 has the potential for the research of related diseases, especially autoimmune diseases, inflammatory diseases or cancer (extracted from patent WO2022063101A1, compound Z2)[1].

分子量

487.94

Formula

C26H22ClN5O3
CAS 号

2765852-46-6
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Fusheng Zhou, et al. Aroyl substituted tricyclic compound, preparation method therefor and use thereof. Patent WO2022063101A1.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

BTK-IN-14

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

BTK-IN-14 

BTK-IN-14 是一种有效的 BTK 抑制剂。BTK 在分别由 B 细胞和骨髓细胞中的B细胞抗原受体 (BCR) 和 Fcγ 受体 (FcγR) 介导的信号传导中起重要作用。BTK-IN-14 具有研究相关疾病的潜力，尤其是自身免疫性疾病、炎症性疾病或癌症 (摘自专利 WO2022057894A1，化合物 1)。

BTK-IN-14

BTK-IN-14 Chemical Structure

CAS No. : 2764674-60-2

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

BTK-IN-14 is a potent inhibitor of BTK. BTK plays an important role in signaling mediated by B cell antigen receptor (BCR) and Fcγreceptor (FcγR) in B cells and myeloid cells, respectively. BTK-IN-14 has the potential for the research of related diseases, especially autoimmune diseases, inflammatory diseases or cancer (extracted from patent WO2022057894A1, compound 1)[1].

分子量

676.81

Formula

C38H44N8O4
CAS 号

2764674-60-2
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Guangxiu Dai, et al. Heteroaryl heterocyclic compounds and uses thereof. Patent WO2022057894A1.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

BTK-IN-10

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

BTK-IN-10 

BTK-IN-10 是一种有效的 BTK 抑制剂，对野生型 BTK 或突变型 BTK (C481S) 的 IC50 值均小于 5 nM (WO2022012509A1; example 111)。

BTK-IN-10

BTK-IN-10 Chemical Structure

CAS No. : 2758596-07-3

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

BTK-IN-10 is a potent BTK inhibitor with IC50s of <5 nm for wild-type btk or mutated (c481s), respectively (wo2022012509a1; example 111)[1].

分子量

450.48

Formula

C25H24F2N4O2
CAS 号

2758596-07-3
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Chunchao Yue, et al. Compound as brain-permeable btk or her2 inhibitor, preparation method therefor, and use thereof. WO2022012509A1.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

BTK-IN-12

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

BTK-IN-12 

BTK-IN-12 是一种有效的 BTK 抑制剂，对野生型 BTK 或突变型 BTK (C481S) 的 IC50 分别为 1.2 nM 和 0.8 nM (WO2022037649A1; compound 8)。

BTK-IN-12

BTK-IN-12 Chemical Structure

CAS No. : 2762043-53-6

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

BTK-IN-12 is a potent BTK inhibitor with IC50s of 1.2 nM and 0.8 nM for wild-type BTK or mutated BTK (C481S), respectively (WO2022037649A1; compound 8)[1].

分子量

505.54

Formula

C27H28FN5O4
CAS 号

2762043-53-6
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Xiangyang Chen, et al. Heterocyclic compounds as btk inhibitors. WO2022037649A1.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

BCPyr

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

BCPyr 

BCPyr 是一种新的候选 BTK 降解剂 （DC50 = 800 nM）。

BCPyr

BCPyr Chemical Structure

CAS No. : 2669844-82-8

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

BCPyr is a new candidate BTK degrader (DC50 = 800 nM).

分子量

1082.20

Formula

C58H65F2N11O8
CAS 号

2669844-82-8
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Schiemer J, et al. Snapshots and ensembles of BTK and cIAP1 protein degrader ternary complexes. Nat Chem Biol. 2021 Feb;17(2):152-160.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

BCPyr

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

BCPyr 

BCPyr 是一种新的候选 BTK 降解剂 （DC50 = 800 nM）。

BCPyr

BCPyr Chemical Structure

CAS No. : 2669844-82-8

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

BCPyr is a new candidate BTK degrader (DC50 = 800 nM).

分子量

1082.20

Formula

C58H65F2N11O8
CAS 号

2669844-82-8
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Schiemer J, et al. Snapshots and ensembles of BTK and cIAP1 protein degrader ternary complexes. Nat Chem Biol. 2021 Feb;17(2):152-160.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

BCPyr

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

BCPyr 

BCPyr 是一种新的候选 BTK 降解剂 （DC50 = 800 nM）。

BCPyr

BCPyr Chemical Structure

CAS No. : 2669844-82-8

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

BCPyr is a new candidate BTK degrader (DC50 = 800 nM).

分子量

1082.20

Formula

C58H65F2N11O8
CAS 号

2669844-82-8
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Schiemer J, et al. Snapshots and ensembles of BTK and cIAP1 protein degrader ternary complexes. Nat Chem Biol. 2021 Feb;17(2):152-160.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

BTK-IN-7

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

BTK-IN-7 

BTK-IN-7 是一种有效的选择性 BTK 抑制剂 (IC50=4.0 nM)，BTK-IN-7在酶 (ITK >250-fold, EGFR >2500-fold) 和细胞水平 (ITK >227-fold, EGFR 27-fold) 都具有较高的选择性。BTK-IN-7还具有较高的抗肿瘤活性。

BTK-IN-7

BTK-IN-7 Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

BTK-IN-7 is a potent and selective inhibitor of BTK (IC50=4.0 nM). BTK-IN-7 has high selectivity in both enzymatic (ITK >250-fold, EGFR >2500-fold) and cellular levels(ITK >227-fold, EGFR 27-fold). BTK-IN-7 also has potent antitumor activity[1].

体外研究
(In Vitro)

BTK-IN-7 (compound 24a; 10, 100, 1000, 10000 nM; 48 hours) displays the antiproliferative effects in U-937 cells (IC50=3.6 μM)[1]. BTK-IN-7 (10, 100, 1000, 10000 nM; 48 hours; U937 cells) induces cell cycle arrest at the G1 phase in a concentration-dependent manner[1]. BTK-IN-7 (1-5 μM; 48 hours) induces apoptosis in U-937 cells[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[1]

Cell Line: U937, Ramos, Pfeiffer, Jeko-1 cells
Concentration: 10, 100, 1000, 10000 nM
Incubation Time: 48 hours
Result: Displayed antiproliferative effects in U-937 (IC50=3.6 μM) cells.

Cell Cycle Analysis[1]

Cell Line: U937 cells
Concentration: 10, 100, 1000, 10000 nM
Incubation Time: 48 hours
Result: Cells were arrested atthe G1 phase in a concentration-dependent manner.

Apoptosis Analysis[1]

Cell Line: U937 cells
Concentration: 1, 2.5, 5 μM
Incubation Time: 48 hours
Result: An apoptosis rate was increased to 22.75% at a concentration of 5 μM.

体内研究
(In Vivo)

BTK-IN-7 (25 and 50 mg/kg; intraperitoneal injection; daily for 14 days) inhibits tumor growth in a dose-dependent manner in U-937 xenograft mouse model, and 50 mg/kg dosage displays a better antitumor effect. BTK-IN-7 does not show significant parenchymal injury or inflammatory cell infiltration in organs[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male BALB/c nude mice (U397 xenograft mouse model) [1]
Dosage: 25, 50 mg/kg
Administration: Intraperitoneal injection; daily for 14 days
Result: Inhibited tumor growth in a dose-dependent manner and did not reveal significant parenchymal injury or inflammatory cell infiltration in organs.

分子量

540.61

Formula

C30H32N6O4
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Dou D, et al. Discovery of Pteridine-7(8H)-one Derivatives as Potent and Selective Inhibitors of Bruton’s Tyrosine Kinase (BTK). J Med Chem. 2022;65(3):2694-2709.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

BTK-IN-7

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

BTK-IN-7 

BTK-IN-7 是一种有效的选择性 BTK 抑制剂 (IC50=4.0 nM)，BTK-IN-7在酶 (ITK >250-fold, EGFR >2500-fold) 和细胞水平 (ITK >227-fold, EGFR 27-fold) 都具有较高的选择性。BTK-IN-7还具有较高的抗肿瘤活性。

BTK-IN-7

BTK-IN-7 Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

BTK-IN-7 is a potent and selective inhibitor of BTK (IC50=4.0 nM). BTK-IN-7 has high selectivity in both enzymatic (ITK >250-fold, EGFR >2500-fold) and cellular levels(ITK >227-fold, EGFR 27-fold). BTK-IN-7 also has potent antitumor activity[1].

体外研究
(In Vitro)

BTK-IN-7 (compound 24a; 10, 100, 1000, 10000 nM; 48 hours) displays the antiproliferative effects in U-937 cells (IC50=3.6 μM)[1]. BTK-IN-7 (10, 100, 1000, 10000 nM; 48 hours; U937 cells) induces cell cycle arrest at the G1 phase in a concentration-dependent manner[1]. BTK-IN-7 (1-5 μM; 48 hours) induces apoptosis in U-937 cells[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[1]

Cell Line: U937, Ramos, Pfeiffer, Jeko-1 cells
Concentration: 10, 100, 1000, 10000 nM
Incubation Time: 48 hours
Result: Displayed antiproliferative effects in U-937 (IC50=3.6 μM) cells.

Cell Cycle Analysis[1]

Cell Line: U937 cells
Concentration: 10, 100, 1000, 10000 nM
Incubation Time: 48 hours
Result: Cells were arrested atthe G1 phase in a concentration-dependent manner.

Apoptosis Analysis[1]

Cell Line: U937 cells
Concentration: 1, 2.5, 5 μM
Incubation Time: 48 hours
Result: An apoptosis rate was increased to 22.75% at a concentration of 5 μM.

体内研究
(In Vivo)

BTK-IN-7 (25 and 50 mg/kg; intraperitoneal injection; daily for 14 days) inhibits tumor growth in a dose-dependent manner in U-937 xenograft mouse model, and 50 mg/kg dosage displays a better antitumor effect. BTK-IN-7 does not show significant parenchymal injury or inflammatory cell infiltration in organs[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male BALB/c nude mice (U397 xenograft mouse model) [1]
Dosage: 25, 50 mg/kg
Administration: Intraperitoneal injection; daily for 14 days
Result: Inhibited tumor growth in a dose-dependent manner and did not reveal significant parenchymal injury or inflammatory cell infiltration in organs.

分子量

540.61

Formula

C30H32N6O4
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Dou D, et al. Discovery of Pteridine-7(8H)-one Derivatives as Potent and Selective Inhibitors of Bruton’s Tyrosine Kinase (BTK). J Med Chem. 2022;65(3):2694-2709.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

BTK-IN-7

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

BTK-IN-7 

BTK-IN-7 是一种有效的选择性 BTK 抑制剂 (IC50=4.0 nM)，BTK-IN-7在酶 (ITK >250-fold, EGFR >2500-fold) 和细胞水平 (ITK >227-fold, EGFR 27-fold) 都具有较高的选择性。BTK-IN-7还具有较高的抗肿瘤活性。

BTK-IN-7

BTK-IN-7 Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

BTK-IN-7 is a potent and selective inhibitor of BTK (IC50=4.0 nM). BTK-IN-7 has high selectivity in both enzymatic (ITK >250-fold, EGFR >2500-fold) and cellular levels(ITK >227-fold, EGFR 27-fold). BTK-IN-7 also has potent antitumor activity[1].

体外研究
(In Vitro)

BTK-IN-7 (compound 24a; 10, 100, 1000, 10000 nM; 48 hours) displays the antiproliferative effects in U-937 cells (IC50=3.6 μM)[1]. BTK-IN-7 (10, 100, 1000, 10000 nM; 48 hours; U937 cells) induces cell cycle arrest at the G1 phase in a concentration-dependent manner[1]. BTK-IN-7 (1-5 μM; 48 hours) induces apoptosis in U-937 cells[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[1]

Cell Line: U937, Ramos, Pfeiffer, Jeko-1 cells
Concentration: 10, 100, 1000, 10000 nM
Incubation Time: 48 hours
Result: Displayed antiproliferative effects in U-937 (IC50=3.6 μM) cells.

Cell Cycle Analysis[1]

Cell Line: U937 cells
Concentration: 10, 100, 1000, 10000 nM
Incubation Time: 48 hours
Result: Cells were arrested atthe G1 phase in a concentration-dependent manner.

Apoptosis Analysis[1]

Cell Line: U937 cells
Concentration: 1, 2.5, 5 μM
Incubation Time: 48 hours
Result: An apoptosis rate was increased to 22.75% at a concentration of 5 μM.

体内研究
(In Vivo)

BTK-IN-7 (25 and 50 mg/kg; intraperitoneal injection; daily for 14 days) inhibits tumor growth in a dose-dependent manner in U-937 xenograft mouse model, and 50 mg/kg dosage displays a better antitumor effect. BTK-IN-7 does not show significant parenchymal injury or inflammatory cell infiltration in organs[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male BALB/c nude mice (U397 xenograft mouse model) [1]
Dosage: 25, 50 mg/kg
Administration: Intraperitoneal injection; daily for 14 days
Result: Inhibited tumor growth in a dose-dependent manner and did not reveal significant parenchymal injury or inflammatory cell infiltration in organs.

分子量

540.61

Formula

C30H32N6O4
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Dou D, et al. Discovery of Pteridine-7(8H)-one Derivatives as Potent and Selective Inhibitors of Bruton’s Tyrosine Kinase (BTK). J Med Chem. 2022;65(3):2694-2709.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

BTK-IN-9

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

BTK-IN-9 

BTK-IN-9 是一种可逆的 BTK 抑制剂，在套细胞淋巴瘤细胞中中具有较强的抗增殖活性。BTK-IN-9 特异性地扰乱线粒体膜电位并增加 Z138 细胞中的活性氧水平。BTK-IN-9 还诱导 Z138 细胞中的细胞凋亡。

BTK-IN-9

BTK-IN-9 Chemical Structure

CAS No. : 2361192-21-2

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

BTK-IN-9 is a reversible BTK inhibitors with potent antiproliferative activity in mantle cell lymphoma. BTK-IN-9 specifically disturbs mitochondrial membrane potential and increases reactive oxygen species level in Z138 cells. BTK-IN-9 also induces cell apoptosis in Z138 cells[1].

分子量

481.46

Formula

C25H19N7O4
CAS 号

2361192-21-2
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Ran F, et al. Design and synthesis of novel pyrazolopyrimidine-based derivatives as reversible BTK inhibitors with potent antiproliferative activity in mantle cell lymphoma. Med Chem Res, 2022, 31, 594-604.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务